Visiongain has released its new Biopharmaceuticals Contract Manufacturing Market Report 2026-2036, forecasting that the global market will reach US$69.11bn by 2036 from US$20.89bn in 2026.

The market is forecast to expand at a compound annual growth rate (CAGR) of 12.7% between 2026 and 2036, driven by rising investment by CMOs in capacity expansion, increasing outsourcing by pharmaceutical and biotechnology companies, the adoption of advanced manufacturing technologies, and growing demand across emerging economies in Asia Pacific.

Key Market Growth Drivers & Industry Transformations

Rise in Investment by CMOs for Capacity Expansion: The rise of early-stage biopharmaceutical companies, supported by advances in biotechnology platforms and sustained investment activity, is increasing demand for outsourced manufacturing services. Contract manufacturers are expanding their manufacturing footprint while strengthening specialised capabilities across high-growth biologic modalities, including high-potency containment facilities for ADCs, dedicated mRNA manufacturing platforms, and flexible aseptic fill-finish technologies. South Korea’s Ministry of Food and Drug Safety reported that the country’s biopharmaceutical exports reached a record US$4.5bn in the first half of 2026, increasing by 15.3% year on year, supported in part by expanded CDMO supply and growing demand for biologics and biosimilars.

Outsourcing as a Driver for Market Growth: The cost and operational advantages of outsourcing continue to make it a key growth driver for the biopharmaceutical contract manufacturing market. CDMOs operate flexible, multi-product facilities equipped with modular production technologies, single-use systems, and dedicated fill-finish capabilities, allowing multiple programmes to be executed simultaneously while improving asset utilisation and reducing operational overheads. In January 2025, Novo Holdings outlined plans to approximately double the size of Catalent over the next five years to address increasing outsourcing demand and strengthen global manufacturing capabilities.

Advancements in Manufacturing Technologies Strengthen Contract Manufacturing Value Proposition: Technological innovation continues to reshape the biopharmaceutical contract manufacturing landscape, enabling service providers to improve operational efficiency, enhance product quality, and support increasing demand for complex biologic therapies. The adoption of continuous bioprocessing, advanced automation, Process Analytical Technology (PAT), and Quality by Design (QbD) frameworks is strengthening process control and manufacturing reliability across biologics production. In October 2025, Samsung Biologics launched ExellenS, an integrated manufacturing framework designed to standardise equipment, processes, and operating specifications across its global production network, improving manufacturing consistency and facilitating commercial scale-up.

Emerging Economies to Offer Lucrative Growth Opportunities: Emerging economies, particularly across Asia Pacific, are becoming increasingly important to the global biopharmaceutical contract manufacturing landscape. Countries such as India, South Korea, and China are strengthening their position through expanding manufacturing capabilities, improving regulatory compliance, and growing expertise in complex biologics production. In July 2026, Formycon AG entered into a strategic manufacturing partnership with OneSource Specialty Pharma for the development and commercial manufacture of biosimilars, with OneSource providing integrated drug substance and drug product manufacturing services from its Bengaluru facility in India, reinforcing the country’s growing role as a global hub for outsourced biopharmaceutical manufacturing.

What This Means for the Biopharmaceuticals Contract Manufacturing Market

The biopharmaceuticals contract manufacturing market is entering a period of sustained structural growth as biologics pipelines expand, commercial manufacturing programmes accumulate, and pharmaceutical and biotechnology companies increasingly rely on specialist CDMOs for integrated end-to-end services. CDMOs that combine technical breadth across multiple biologic modalities, advanced digital manufacturing capabilities, geographically diversified production networks, and strong regulatory track records are best positioned to capture long-term programme value over the next decade.

Scope of the Visiongain Report

The 425-page report provides robust quantitative and qualitative analysis across all key facets of the global biopharmaceuticals contract manufacturing market:

By Source: Mammalian; Non-mammalian.

By Service: Process Development; Downstream; Upstream; Fill & Finish Operations; Analytical & QC Studies; Packaging.

By Product: Biologics (Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Others); Biosimilars.

By Company Size: Small; Mid-sized; Large.

By Scale of Operations: Preclinical; Clinical; Commercial.

By Therapeutic Area: Oncology; Autoimmune Diseases; Cardiovascular Diseases; Metabolic Diseases; Infectious Diseases; Neurology; Others.

By Regional & Country Markets: North America, Europe, Asia Pacific, Latin America, and MEA.

Competitive Landscape

The competitive environment is characterised by global CDMOs, integrated biologics manufacturers, and specialist service providers across drug substance, formulation, and fill-finish. Companies profiled in the report include:

• AbbVie Inc.
• AGC Biologics
• Avantor, Inc.
• Boehringer Ingelheim GmbH
• Bynex Co., Ltd.
• Cambrex Corporation
• Catalent, Inc. (A Novo Holdings Company)
• Curia Global, Inc.
• Cytiva
• FUJIFILM Diosynth Biotechnologies
• JRS Pharma
• Jubilant Pharma Limited
• KBI Biopharma
• Lonza
• Pfizer CentreOne
• ProBioGen AG
• Rentschler Biopharma SE
• Samsung Biologics
• Sandoz Group AG
• Thermo Fisher Scientific Inc.
• TOYOBO CO., LTD.
• WuXi Biologics

Recent Developments

• 25 Jun 2026 – Samsung Biologics announced it will add new CMO orders to its Rockville, Maryland facility while pursuing further global expansion. The U.S. site will manufacture both commercial pharmaceutical products and additional biologics under contract manufacturing agreements, strengthening its regional footprint and enhancing proximity to North American customers.

• 15 Apr 2026 – TheraNym Biologics announced plans to invest US$150-175 million in a new biologic drug substance manufacturing facility under its existing contract manufacturing agreement with MSD. The greenfield facility will include approximately 60,000 litres of mammalian cell culture bioreactor capacity together with advanced downstream purification infrastructure.

• 1 Apr 2026 – Samsung Biologics completed the acquisition of GSK’s biopharmaceutical manufacturing facility in Rockville, Maryland, establishing its first manufacturing presence in the United States. The acquisition adds two cGMP manufacturing plants with a combined drug substance capacity of 60,000 litres, increasing the company’s total global manufacturing capacity to 845,000 litres.

• 13 Jan 2026 – Rakuten Medical and LOTTE Biologics signed a biopharmaceutical contract manufacturing agreement to support Rakuten Medical’s global oncology programme. LOTTE Biologics will provide manufacturing services for monoclonal antibody intermediates and their conjugates, supported through its specialised ADC manufacturing facility at the Syracuse Bio Campus in New York.

Related Reports

• Antibody Drug Conjugates Contract Manufacturing Market 2026-2036
• Protein Contract Manufacturing Market 2026-2036
• Peptide Contract Manufacturing Market 2026-2036
• mRNA Contract Manufacturing Market 2026-2036

About Visiongain

Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.

Media Contact

press@visiongain.com
+44 (0)20 7336 6100
www.visiongain.com